Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT00335504
This randomized phase II trial is studying atorvastatin calcium to see how well it works compared to oligofructose-enriched inulin, sulindac, or a placebo in preventing cancer in patients at increased risk of developing colorectal neoplasia. Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of atorvastatin calcium, oligofructose-enriched inulin, or sulindac may stop cancer from forming in patients at increased risk of colorectal neoplasia. It is not yet known whether atorvastatin calcium, oligofructose-enriched inulin, or sulindac are more effective than a placebo in preventing cancer in patients at increased risk of developing colorectal neoplasia.
Intervention
atorvastatin calcium, laboratory biomarker analysis, oligofructose-enriched inulin, placebo, sulindac
Condition
Colon Cancer, Precancerous Condition, Rectal Cancer
Investigators
Paul Limburg